Oxford Cannabinoid Technologies Holdings Plc (OCTHF) 是一家上市公司 属于 医疗保健 板块，经营于 生物科技 行业. 公司总部位于 London, 英国. 现任CEO为 Clarissa Ann Sowemimo-Coker.
OCTHF 拥有 IPO日期为 2021-10-20, 5 名全职员工, 在 Other OTC, 市值为 $3.05M.
Oxford Cannabinoid Technologies Holdings Plc, a pharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based prescription medicines. Its lead drug candidate is OCT461201, a selective CB2 receptor agonist in solid oral dosage form that is in pre-clinical development for use in the treatment of IBS-associated visceral pain, as well as neuropathic pain conditions, including post herpetic neuralgia. The company is also developing OCT130401, which is in pre-clinical development for the treatment of trigeminal neuralgia. Oxford Cannabinoid Technologies Holdings Plc was incorporated in 2017 and is headquartered in London, the United Kingdom.
